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Introduction {#s1}
============

Antigen-presenting cells (APCs) are critical for both innate and adaptive immunity. Professional APCs such as macrophages play an integral role in the immune pathogenesis of the human immunodeficiency virus type 1 (HIV-1) [@pone.0106418-Herbein1]. HIV-1 is a member of the lentivirus family and is the etiologic agent of acquired immunodeficiency syndrome (AIDS). It interacts with host cells through multiple signaling pathways to establish the disease [@pone.0106418-Kilareski1]. The infection involves complex mechanisms through which HIV-1 overcomes the host immune responses and causes reprogramming of the host transcriptome and proteome [@pone.0106418-Barrero1]--[@pone.0106418-VandenBergh1].

Vpr, an accessory gene product of HIV-1, is a protein of 96 amino acids and has a predicted molecular weight of 15 kDa that is relatively conserved in HIV-1 and simian immunodeficiency virus (SIV) [@pone.0106418-Tristem1]. Vpr is a pleiotropic protein that is involved in diverse functions including cell-cycle arrest at the G2/M phase [@pone.0106418-Murakami1], apoptosis [@pone.0106418-Murakami1]--[@pone.0106418-Nishizawa1], nuclear import of the pre-integration complex [@pone.0106418-Aida1]--[@pone.0106418-Kamata1], transcriptional activation [@pone.0106418-Felzien1], and splicing [@pone.0106418-Hashizume1], [@pone.0106418-Kuramitsu1]. Vpr performs these functions through interactions with various host cellular factors such as DCAF1, SAP145, p300, and importin-α [@pone.0106418-Nonaka1], [@pone.0106418-Aida1], [@pone.0106418-NitaharaKasahara1], .

A striking feature of Vpr is its unique potential to promote viral productivity in monocytes/macrophages and in a small population of CD4^+^ T-cells [@pone.0106418-Balotta1]--[@pone.0106418-Zhou1]. Although Vpr is thought to play an important role in HIV-1-infected human macrophages [@pone.0106418-Herbein1], [@pone.0106418-Barrero1], [@pone.0106418-Tristem1], [@pone.0106418-NitaharaKasahara1], [@pone.0106418-Sherman1], [@pone.0106418-Connor1], little is known about how it disrupts the expression profile of host cellular genes. In this study, we analyzed the effect of Vpr on the expression profiles of host cellular genes in human monocyte-derived macrophages (MDMs), with the idea that such an analysis would provide useful information about the involvement of genes not yet identified through biochemical approaches. Human MDMs were generated from peripheral blood mononuclear cells (PBMCs) and infected with a recombinant adenovirus expressing Vpr, and analyzed by cDNA microarray. HIV-1 Vpr protein induced interferon (IFN)-stimulated genes (ISGs) such as *IRF7*, and caused phosphorylation of STAT1 at tyrosine 701 in human MDMs. These findings enhance the current understanding of HIV-1 replication and pathogenesis in human macrophages.

Results {#s2}
=======

Expression of Vpr and ZsGreen1 in human MDMs {#s2a}
--------------------------------------------

To better understand the role of HIV-1 Vpr protein in human MDMs, a recombinant adenovirus expressing ZsGreen1 and FLAG-tagged Vpr, Ad-Vpr, was generated. As a control, a recombinant adenovirus expressing ZsGreen1, Ad-Zs, was used. A schematic diagram of both recombinant adenoviruses is shown in [Figure 1A](#pone-0106418-g001){ref-type="fig"}. To examine whether Vpr induces cell-cycle arrest at the G2 phase, HeLa cells were infected with Ad-Vpr or Ad-Zs at a multiplicity of infection (MOI) of 50. At 48 h post-infection, cells were harvested for analysis of DNA content and stained with propidium iodide (PI). The DNA content of ZsGreen1-positive cells was analyzed by flow cytometry, which revealed a dramatic increase in the proportion of cells in the G2 phase of the cell cycle in cells infected with Ad-Vpr (21.22% and 70.37% were in the G1 and the G2+M phases, respectively, and the G2+M: G1 ratio was 3.32) compared to cells infected with the control Ad-Zs (54.06% and 23.87% were in the G1 and G2/M phases, respectively, and the G2+M: G1 ratio was 0.44) ([Figure 1B](#pone-0106418-g001){ref-type="fig"}). These results indicate that the recombinant adenovirus expressing FLAG-Vpr induces G2 cell-cycle arrest.

![Schematic diagram of the Ad-Vpr and Ad-Zs vectors and analysis of their functional expression.\
(A) Recombinant adenovirus vectors expressing either FLAG-Vpr and ZsGreen1 or ZsGreen1 were generated using the Adeno-X™ expression system, as described in Materials and Methods. The transgene cassettes that replace the deleted E1 region contain a cytomegalovirus (CMV) promoter driving the expression of FLAG-Vpr and ZsGreen1 or ZsGreen1 protein, followed by an SV40 polyadenylation signal. The solid triangles indicate the regions deleted in the recombinant adenovirus (rAd) backbone. ITR: Inverted terminal repeats. (B) HeLa cells were infected with Ad-Vpr or Ad-Zs at MOI 50. At 48 h post-infection, cells were fixed and stained with propidium iodide for the analysis of DNA content. ZsGreen1-positive cells were analyzed by flow cytometry using Cell Quest for acquisition and ModFit LT. Arrowheads indicate peaks representing cells in the G1 and G2+M phases. The G2+M: G1 ratio is indicated in the upper right of each graph.](pone.0106418.g001){#pone-0106418-g001}

Purified and titrated Ad-Vpr and Ad-Zs were next used to infect MDMs derived from peripheral blood monocytes from two normal healthy donors ([Figure 2](#pone-0106418-g002){ref-type="fig"}). PBMCs were isolated from heparinized whole blood from two healthy donors by standard density gradient centrifugation with Ficoll-Paque. PBMCs were harvested from the interface and CD14^+^ cells were separated by high-gradient magnetic sorting using MACS beads. The isolated CD14^+^ cells were differentiated into MDMs for 7 days, and then infected with the Ad-Vpr or Ad-Zs at a MOI of 100. After 48 h, the cells were either observed under a fluorescence microscope or lysed and analyzed for the expression of Vpr and ZsGreen1 protein by Western blotting. Fluorescence microscopy showed that ZsGreen1 was expressed in both Ad-Vpr- and Ad-Zs-infected MDMs compared to mock-infected controls, which remained ZsGreen1-negative ([Figure 2A](#pone-0106418-g002){ref-type="fig"}). As shown in [Figure 2B](#pone-0106418-g002){ref-type="fig"}, a 26 kDa band representing ZsGreen1 and a 14 kDa band representing Vpr was detected; these apparent molecular masses are consistent with their respective predicted sequences. Further, there was no difference in ZsGreen1 expression between the two populations of MDMs ([Figure 2B](#pone-0106418-g002){ref-type="fig"}). These results confirm the suitability of the adenovirus-infected MDMs for downstream assays.

![Expression analyses of HIV-1 Vpr protein in human monocyte-derived macrophages (MDMs).\
(A) Peripheral blood mononuclear cells (PBMCs) were isolated from two healthy donors through leukophoresis, cultured *in vitro*, and differentiated into MDMs as described in Materials and Methods. At day 7, the MDMs were infected with either Ad-Vpr or Ad-Zs, or were left untreated as mock-infected controls (left). At 48 h post-infection, the cells from Donor 1 were visualized by fluorescence (FL) and bright field phase contrast (BF) microscopy. (B) The cells from the two donors (upper panel, Donor 1; lower panel, Donor 2) were lysed and subjected to Western blot analyses using Vpr, ZsGreen1, and β-actin antibodies.](pone.0106418.g002){#pone-0106418-g002}

Microarray analysis of MDMs infected with Ad-Vpr or Ad-Zs {#s2b}
---------------------------------------------------------

To evaluate changes in the expression of host cellular genes in response to HIV-1 Vpr protein, Ad-Vpr- and Ad-Zs-infected macrophages were subjected to cDNA microarray analyses using a commercially available Affymetrix GeneChip oligonucleotide array (Human Genome U133 Plus 2.0), which interrogates more than 47,000 transcripts from 38,500 genes. This approach enabled us to monitor Vpr-induced changes in the global gene profile of the MDMs. Data analysis using GeneSpring GX software showed that Vpr modulated the expression of 557 genes in Donor 1 and 116 genes in Donor 2. Given that the array analyzes more than 47,000 gene transcripts, this is considered a minor change in the global host gene profiles ([Figure 3](#pone-0106418-g003){ref-type="fig"}). Heat maps from both donors ([Figure 3](#pone-0106418-g003){ref-type="fig"}) show that the global gene expression profiles were different in each donor, indicating that there is individual variability in the response to Vpr at the transcriptional level.

![Differential expression profiling of cellular genes after infection with Ad-Vpr in human monocyte-derived macrophages (MDMs).\
Heat map of hierarchical gene clustering showing all genes that were either up- or down-regulated (\>2-fold change) upon Ad-Vpr infection in MDMs from both donors. The color represents the normalized expression of genes in MDMs infected with Ad-Vpr or Ad-Zs (see color key). Gene up-regulation is denoted in red and gene down-regulation is denoted in blue.](pone.0106418.g003){#pone-0106418-g003}

The differentially regulated genes were filtered to determine gene entities common to both donors. Out of 557 genes altered in response to Vpr in Donor 1 and 116 genes in Donor 2, only 66 genes were common to both ([Figure 4A](#pone-0106418-g004){ref-type="fig"}). Gene ontology was ranked based on the corrected p-values. The ten most significant pathways common to both donors are shown in [Figure 4B](#pone-0106418-g004){ref-type="fig"}. HIV-1 Vpr significantly altered the expression profiles of cellular genes mainly involved in the innate immune response, type I IFN signaling, and cytokine-mediated signaling. A complete list of all 66 genes common to both donors is shown in the form of heat maps in [Figure 4C](#pone-0106418-g004){ref-type="fig"}.

![Gene ontology of differentially expressed genes after infection of human monocyte-derived macrophages (MDMs) with Ad-Vpr.\
(A) Venn diagram representing the number of differentially expressed cellular genes (\>2-fold change in both donors) after infection of human MDMs with Ad-Vpr. (B) The top ten genes ontology classified by corrected p-value, and (C) heat map of hierarchical gene clustering of the 66 differentially regulated in both donors. Gene up-regulation is denoted in red and gene down-regulation is denoted in blue.](pone.0106418.g004){#pone-0106418-g004}

Most of the altered genes were involved in the immune response or the defense response ([Figure 4B](#pone-0106418-g004){ref-type="fig"}); therefore, genes related to the immune response (GO: 0006955) were further analysed. A complete list of the 126 and 41 genes differentially regulated in Donor 1 and Donor 2 respectively, is shown in [Table 1](#pone-0106418-t001){ref-type="table"}. A significant majority of the up-regulated genes are involved in the immune response. *IFI44L* (40-fold), *CXCL10* (23-fold), *MX1* (15-fold), *CCL8* (13-fold), *IFIT1* (10-fold), *TNFSF10* (TRAIL) (8-fold), *ISG20* (8-fold), *IFIT2* (8-fold), *APOBEC3A* (7-fold), *CXCL11* (7-fold), *IFI27* (7-fold), *OAS2* (7-fold), *IRF7* (6-fold), and *ISG15* (5-fold) were the most highly up-regulated genes, whereas *PPBP*(CXCL7) (96-fold), *MARCO* (13-fold), *CXCL5* (7-fold), *MT2A* (6-fold), and *CCL22* (4-fold) were the most highly down-regulated genes in Donor 1 ([Table 1](#pone-0106418-t001){ref-type="table"}). In contrast, *IFI44L* (12-fold), *MX1* (7-fold), *APOBEC3A* (6-fold), *IFIT1* (5-fold), *IFIT2* (4.5-fold), *IFIT3* (4-fold), *ISG15* (3-fold), *XAF1* (3-fold), *OAS3* (3-fold), *CCL8* (3-fold), *OAS2* (3-fold), *DDX58* (2.5-fold), *STAT1* (2-fold), *MX2* (2-fold), *IRF7* (2-fold) and *CCL2* (2-fold) were the most highly up-regulated genes, whereas *THBS1* (3-fold), *HLA-DQA* (3-fold), *TLR7* (2.6-fold), *CD74* (2.5-fold), *CXCL2* (2-fold), *CCR2* (2-fold) and *CXCL9* (2-fold) were the most highly down-regulated genes in Donor 2 ([Table 1](#pone-0106418-t001){ref-type="table"}). By close examination of the data set ([Figure 5](#pone-0106418-g005){ref-type="fig"} and [Table 1](#pone-0106418-t001){ref-type="table"}), it was observed that several ISGs, which are mainly produced in response to type I interferon [@pone.0106418-Schoggins1], were up-regulated in the Vpr-expressing MDMs. A hierarchical heat map of all the genes up-regulated in Donor 1 (\>2.0-fold change) that are related to the immune response and type 1 IFN signalling is shown in [Figure 5A and B](#pone-0106418-g005){ref-type="fig"}. Collectively, microarray analyses indicate that HIV-1 Vpr leads to the differential regulation of genes involved in innate immunity, type I IFNs, cytokine production, and cell signalling, resulting in activation of antiviral responses in MDMs.

![Differential expression profiling of cellular genes involved in the immune response and the type I interferon pathway after infection with Ad-Vpr in human monocyte-derived macrophages (MDMs) from Donor 1.\
Heat map showing genes related to the immune response (left: GO: 0006955) and the type I interferon signaling (right: GO: 0060337) that were either up- or down-regulated (\>2-fold change) upon Ad-Vpr infection of MDMs from Donor 1. The color coding represents the normalized expression of genes in MDMs infected with Ad-Vpr or Ad-Zs (see color key). Gene up-regulation is denoted in red and gene down-regulation is denoted in blue.](pone.0106418.g005){#pone-0106418-g005}

10.1371/journal.pone.0106418.t001

###### Differentially expressed genes (fold change \>2.0) associated with immune response (GO: 0006955) upon Ad-Vpr infection in Donor 1 and Donor 2.

![](pone.0106418.t001){#pone-0106418-t001-1}

  Probe Set ID    Gene Symbol   Entrez Gene   Fold Change   Regulation  
  -------------- ------------- ------------- ------------- ------------ ---------
  214146_s\_at       PPBP          5473         −96.30                    Down
  205819_at          MARCO         8685         −12.69                    Down
  215101_s\_at       CXCL5         6374          −6.77                    Down
  207852_at          CXCL5         6374          −5.81                    Down
  212185_x\_at       MT2A          4502          −6.16                    Down
  207861_at          CCL22         6367          −4.06                    Down
  214974_x\_at       CXCL5         6374          −4.23                    Down
  219434_at          TREM1         54210         −2.61                    Down
  220491_at          HAMP          57817         −2.66                    Down
  209924_at          CCL18         6362          −2.15                    Down
  32128_at           CCL18         6362          −2.17                    Down
  219725_at          TREM2         54209         −2.01                    Down
  204470_at          CXCL1         2919          −2.10                    Down
  207069_s\_at       SMAD6         4091          −2.07                    Down
  222868_s\_at      IL18BP         10068         −2.07                    Down
  209200_at          MEF2C         4208          2.52                      Up
  209969_s\_at       STAT1         6772          2.59          2.03        Up
  203104_at          CSF1R         1436          2.54                      Up
  206682_at         CLEC10A        10462         2.56                      Up
  202869_at          OAS1          4938          2.75                      Up
  205552_s\_at       OAS1          4938          2.75                      Up
  217552_x\_at        CR1          1378          2.63                      Up
  211656_x\_at     HLA-DQB1        3119          2.68         −2.06      Up/down
  225869_s\_at      UNC93B1        81622         2.70                      Up
  210166_at          TLR5          7100          2.70                      Up
  210889_s\_at      FCGR2B         2213          2.70                      Up
  212998_x\_at     HLA-DQB1        3119          3.12         −2.14      Up/down
  228607_at          OAS2          4939          3.10          2.15        Up
  222793_at          DDX58         23586         2.96          2.09        Up
  235735_at         TNFSF8          944          2.97                      Up
  238581_at          GBP5         115362         3.00                      Up
  206553_at          OAS2          4939          3.01          2.24        Up
  226878_at         HLA-DOA        3111          3.01         −2.37        Up
  223502_s\_at     TNFSF13B        10673         3.03                      Up
  1567628_at         CD74           972          3.04         −2.54      Up/down
  M97935_MA_at       STAT1         6772          2.88                      Up
  201110_s\_at       THBS1         7057          2.86         −3.44      Up/down
  219132_at          PELI2         57161         2.86                      Up
  212671_s\_at     HLA-DQA1        3117          2.84         −2.40        Up
  M97935_MB_at       STAT1         6772          2.84                      Up
  1555464_at         IFIH1         64135         2.84                      Up
  223501_at        TNFSF13B        10673         2.80                      Up
  209823_x\_at     HLA-DQB1        3119          2.82         −2.07      Up/down
  227677_at          JAK3          3718          2.82                      Up
  209392_at          ENPP2         5168          2.32                      Up
  205992_s\_at       IL15          3600          2.31                      Up
  211367_s\_at       CASP1          834          2.31                      Up
  218986_s\_at       DDX60         55601         2.31                      Up
  244485_at        HLA-DPB1        3115          2.25         −2.19        Up
  209619_at          CD74           972          2.28                      Up
  211395_x\_at      FCGR2C         9103          2.28                      Up
  206011_at          CASP1          834          2.36                      Up
  231234_at          CTSC          1075          2.38                      Up
  205382_s\_at        CFD          1675          2.40                      Up
  203915_at          CXCL9         4283          2.43         −2.44      Up/down
  207674_at          FCAR          2204          2.42                      Up
  204961_s\_at       NCF1         653361         2.44                      Up
  215719_x\_at        FAS           355          2.44                      Up
  209189_at           FOS          2353          2.45                      Up
  214786_at         MAP3K1         4214          2.45                      Up
  210992_x\_at      FCGR2C         9103          2.07                      Up
  231577_s\_at       GBP1          2633          2.09                      Up
  202269_x\_at       GBP1          2633          2.03                      Up
  204908_s\_at       BCL3           602          2.04                      Up
  210140_at          CST7          8530          2.04                      Up
  216243_s\_at       IL1RN         3557          2.04                      Up
  220832_at          TLR8          51311         2.05                      Up
  201008_s\_at       TXNIP         10628         2.03                      Up
  216252_x\_at        FAS           355          2.02                      Up
  201743_at          CD14           929          2.02                      Up
  202948_at          IL1R1         3554          2.01                      Up
  242234_at          XAF1          54739         2.01                      Up
  209199_s\_at       MEF2C         4208          2.01                      Up
  210146_x\_at      LILRB2         10288         2.01                      Up
  206134_at        ADAMDEC1        27299         2.12                      Up
  200986_at        SERPING1         710          2.13                      Up
  212659_s\_at       IL1RN         3557          2.13                      Up
  216015_s\_at       NLRP3        114548         2.15                      Up
  M97935_3\_at       STAT1         6772          2.14                      Up
  211368_s\_at       CASP1          834          2.15                      Up
  209906_at          C3AR1          719          2.18                      Up
  217371_s\_at       IL15          3600          2.20                      Up
  212764_at          ZEB1          6935          2.23                      Up
  202270_at          GBP1          2633          2.22                      Up
  219209_at          IFIH1         64135         2.22                      Up
  204747_at          IFIT3         3437          4.73          3.70        Up
  219863_at          HERC5         51191         4.71                      Up
  205483_s\_at       ISG15         9636          5.16          3.16        Up
  204994_at           MX2          4600          4.88          2.20        Up
  212203_x\_at      IFITM3         10410         4.93                      Up
  229450_at          IFIT3         3437          5.05          3.70        Up
  206133_at          XAF1          54739         4.99          2.19        Up
  220146_at          TLR7          51284         5.00         −2.58      Up/down
  218983_at          C1RL          51279         5.32                      Up
  201601_x\_at      IFITM1         10581         5.46                      Up
  228617_at          XAF1          54739         5.44          3.02        Up
  208436_s\_at       IRF7          3665          5.87          2.16        Up
  210163_at         CXCL11         6373          5.89                      Up
  33304_at           ISG20         3669          4.29                      Up
  214022_s\_at      IFITM1         8519          4.46                      Up
  218400_at          OAS3          4940          4.41          2.82        Up
  201315_x\_at      IFITM2         10581         3.97                      Up
  207075_at          NLRP3        114548         4.09                      Up
  227697_at          SOCS3         9021          4.17                      Up
  218943_s\_at       DDX58         23586         3.49          2.54        Up
  205660_at          OASL          8638          3.65          2.13        Up
  217502_at          IFIT2         3433          3.59          2.93        Up
  244313_at           CR1          1378          3.59                      Up
  216244_at          IL1RN         3557          3.36                      Up
  219211_at          USP18         11274         3.32          2.26        Up
  M97935_5\_at       STAT1         6772          3.28                      Up
  210797_s\_at       OASL          8638          3.23                      Up
  204439_at         IFI44L         10964         40.44         11.7        Up
  204533_at         CXCL10         3627          22.91                     Up
  202086_at           MX1          4599          14.65         7.07        Up
  214038_at          CCL8          6355          12.93         2.68        Up
  226757_at          IFIT2         3433          7.64          4.52        Up
  210873_x\_at     APOBEC3A       200315         7.49          5.67        Up
  211122_s\_at      CXCL11         6373          7.45                      Up
  202411_at          IFI27         3429          7.03          2.14        Up
  204972_at          OAS2          4939          7.05          2.72        Up
  202687_s\_at      TNFSF10        8743          6.85                      Up
  214329_x\_at      TNFSF10        8743          6.95                      Up
  203153_at          IFIT1         3434          10.06         4.89        Up
  202688_at         TNFSF10        8743          8.34                      Up
  204698_at          ISG20         3669          8.42                      Up
  216598_s\_at       CCL2          6347                        2.16        Up
  236203_at         HLA-DQA      100507718                    −3.46       Down
  213831_at         HLA-DQA      100507718                    −2.12       Down
  209480_at         HLADQB         3119                       −2.03       Down
  209774_at          CXCL2         2920                       −2.06       Down
  211743_s\_at       PRG2          5553                       −2.40       Down
  206978_at          CCR2         729230                      −2.19       Down

Validation of the expression of host genes involved in the type 1 IFN pathway by real-time quantitative reverse transcription-polymerase chain reaction (qRT-PCR) {#s2c}
-----------------------------------------------------------------------------------------------------------------------------------------------------------------

Validation of the results obtained by microarray analysis was performed by qRT-PCR evaluating the mRNA levels of selected up-regulated genes involved in the immune response. Genes were selected for confirmation either because they were known to be induced in response to type I IFN and reportedly involved in the innate immune antiviral response [@pone.0106418-Schoggins1], [@pone.0106418-Sadler1] or because they were common to both donors. The transcriptional levels of 15 genes were measured in Donor 1 by qRT-PCR with the primers listed in [Table 2](#pone-0106418-t002){ref-type="table"}, using *GAPDH* as an internal control. In general, there was a strong correlation between the microarray data and the qRT-PCR data at 48 h post-infection; the two techniques yielded very similar expression profiles for all 15 genes in Donor 1 ([Figure 6](#pone-0106418-g006){ref-type="fig"} and [Table 1](#pone-0106418-t001){ref-type="table"}). However, there were some discrepancies, e.g., the qRT-PCR results showed a slightly higher increase than the microarray analysis for *IFI27*. Similarly, the expression levels of *IFIT1*, *IFI44L*, *MX1*, and *RSAD2* (which encodes the viperin protein) were higher in the microarray data compared to their respective relative expression levels in the qRT-PCR data. On the other hand, in Donor 2 except for *IRF7* (4-fold) and *MX1* (5-fold) higher expression levels of *APOBEC3A* (233-fold), *ISG20* (132-fold), *IFIT2* (97-fold), *IFIT1* (51-fold), *ISG15* (38-fold), *IFI27* (47-fold), *IFI44L* (36-fold), *TNFSF10* (*TRAIL*) (29-fold), *RSAD2* (22-fold), *MX2* (17-fold), *IFIT3* (16-fold), *DDX58* (12-fold) and *STAT1* (5-fold) were observed by qRT-PCR compared to their respective microarray data ([Figure 6](#pone-0106418-g006){ref-type="fig"} and [Table 1](#pone-0106418-t001){ref-type="table"}). These inconsistencies were probably due to the differences in transcripts variants or due to the intrinsic differences between the two techniques, notably in the normalization methods. For microarray experiments, the normalization was based on a large number of genes, whereas in the qRT-PCR experiments, a single housekeeping gene was used as an internal control against which the results were normalized. Overall, the qRT-PCR results were in agreement with the array data i.e. differential up-regulation giving us strong confidence in the interpretation of the gene expression data obtained through microarray.

![Validation of microarray data by qRT-PCR.\
Peripheral blood mononuclear cells (PBMCs) isolated from Donor 1, Donor 2 and three other healthy donors (Donors 3--5) through leukophoresis were cultured *in vitro* and differentiated into human MDMs as described in Materials and Methods. At day 7, the MDMs were infected with Ad-Vpr or Ad-Zs. At 48 h post-infection, RNA was extracted and subjected to qRT-PCR to amplify the selected genes using specific primers. Relative mRNA levels of the indicated genes are shown. Values are expressed as the fold change in Ad-Vpr-infected cells compared to Ad-Zs-infected cells and normalized to the expression of a housekeeping gene (*GAPDH*). The results represent the mean ± standard deviation (SD) of three samples from one experiment (P\<0.05).](pone.0106418.g006){#pone-0106418-g006}

10.1371/journal.pone.0106418.t002

###### Primers used for real-time PCR.

![](pone.0106418.t002){#pone-0106418-t002-2}

  Name               5′ Sequence                 3′ Sequence
  ---------- ---------------------------- -------------------------
  STAT1         CCATCCTTTGGTACAACATGC        TGCACATGGTGGAGTCAGG
  MX1            CAGCACCTGATGGCCTATCA      ACGTCTGGAGCATGAAGAACTG
  MX2          AAACTGTTCAGAGCACGATTGAAG    ACCATCTGCTCCATTCTGAACTG
  ISG15        ACTCATCTTTGCCAGTACAGGAG      CAGCATCTTCACCGTCAGGTC
  ISG20          TCACCCCTCAGCACATGGT       TTCAGGAGCTGCAGGATCTCTAG
  IFIT1          GCAGCCAAGTTTTACCGAAG       GCCCTATCTGGTGATGCAGT
  IFIT2          CGAACAGCTGAGAATTGCAC       CAAGTTCCAGGTGAAATGGC
  IFIT3         AGTCTAGTCACTTGGGGAAAC      ATAAATCTGAGCATCTGAGAGTC
  IFI27          GGCAGCCTTGTGGCTACTCT       ATGGAGCCCAGGATGAACTTG
  IFI44L      GTATAGCATATGTGGCCTTGCTTACT    ATGACCCGGCTTTGAGAAGTC
  TNFSF10       GAGCTGAAGCAGATGCAGGAC       TGACGGAGTTGCCACTTGACT
  RSAD2         AGGTTCTGCAAAGTAGAGTTGC       GATCAGGCTTCCATTGCTC
  APOBEC3A       GAGAAGGGACAAGCACATGG       GTCTTATGCCTTCCAATGCC
  IRF7           TACCATCTACCTGGGCTTCG        AGGGTTCCAGCTTCACCA
  DDX58         ATCCCAGTGTATGAACAGCAG      GCCTGTAACTCTATACCCATGTC
  GAPDH        ACAGTCAGCCGCATCTTCTTTTGC     TTGAGGTCAATGAAGGGGTC

Next, to demonstrate whether similar results could be obtained in other healthy donors, the transcriptional levels of these 15 genes were measured in MDMs derived from three additional healthy donors (Donors 3--5) by qRT-PCR. As shown in [Figure 6](#pone-0106418-g006){ref-type="fig"}, the expression profiles of the three additional donors were generally consistent with the data obtained from Donor 1. However, the expression levels of the *IFI27* and *IFI44L* genes, which were up-regulated approximately 7-fold and 40-fold, respectively, in the presence of Vpr in MDMs derived from Donor 1, were only slightly up-regulated in Donors 3 and 4. These results indicated that the activation of the type I IFN pathway was common to all the tested healthy donors.

Confirmation of protein expression by Western blotting {#s2d}
------------------------------------------------------

Finally, Western blotting was performed to examine the effect of HIV-1 Vpr on the protein expression levels of IRF7, STAT1, ISG15, ISG20, APOBEC3A, and TRAIL in MDMs. Cell lysates were prepared from Ad-Vpr, Ad-Zs, or mock-infected MDMs and subjected to Western blotting using specific antibodies. β-actin was used as a loading control. Consistent with the microarray data and the qRT-PCR results, STAT1, ISG15, ISG20, IRF7, and TRAIL were up-regulated in Ad-Vpr-infected macrophages compared to Ad-Zs- or mock-infected controls ([Figure 7](#pone-0106418-g007){ref-type="fig"}); however, APOBEC3A, which was originally shown to be up-regulated at the transcriptional level by both microarray and real-time PCR, was not induced at the protein level compared to controls, as measured by Western blotting ([Figure 7](#pone-0106418-g007){ref-type="fig"}). Why the *APOBEC3A* gene transcript failed to express its gene product is not clear; however, differential regulation of gene transcription does not ensure a corresponding change in gene product levels. Taken together, these results clearly indicate that HIV-1 Vpr protein leads to the activation of the type I IFN pathway and the subsequent up-regulation of various ISGs in human MDMs.

![Validation of differentially expressed genes at the protein level.\
Human monocyte-derived macrophages (MDMs) were infected with Ad-Vpr or Ad-Zs, or mock-infected as a control. At 48 h post-infection, the cells were washed, lysed, and subjected to Western blot analyses with the indicated antibodies. A β-actin antibody was used as a loading control.](pone.0106418.g007){#pone-0106418-g007}

Discussion {#s3}
==========

The data presented herein are the first analysis of the changes in gene transcription that occur following *in vitro* infection of human MDMs with an adenovirus expressing HIV-1 Vpr protein. Although some previous studies have shown that HIV-1 infection leads to the activation of innate immunity and thus the induction of various ISGs in human MDMs [@pone.0106418-VandenBergh1], [@pone.0106418-Huang1]--[@pone.0106418-Vzquez1], the specific role of Vpr in the induction of ISGs in human MDMs has not been documented.

In this study, by utilizing an Affymetrix oligonucleotide microarray, we demonstrated that the majority of the genes differentially regulated by Ad-Vpr in both donors were involved in the immune response, indicating the important role played by HIV-1 Vpr protein in human MDMs. A large number of genes from this group is predicted to be activated during the innate immune response ([Table 1](#pone-0106418-t001){ref-type="table"}) as part of the host defense response to clear viral infections [@pone.0106418-Schoggins1], [@pone.0106418-Sadler1], [@pone.0106418-Darnell1]. We observed an increase in the levels of various ISGs such as *MX1, IFI44L, DDX58, RSAD2*, and several of the *IFITs*, which have been shown to play an important role against HIV-1 infection in MDMs [@pone.0106418-Nasr1]. MX2 has recently been reported to be an IFN-induced inhibitor of HIV-1 infection in human monocytoid cell lines [@pone.0106418-Kane1]. Since the differential expression levels of the *MX1, MX2, IFIT1, IFIT2, IFIT3, IFIT27, IFI44L, DDX58*, and *RSAD2* genes obtained through microarray strongly correlated with the real-time PCR data, it is reasonable to speculate that the expression of these proteins may be up-regulated following HIV-1 infection in human MDMs.

Real-time PCR data and Western blot analysis confirmed the activation of IRF7 by HIV-1 Vpr in human MDMs ([Figures 6](#pone-0106418-g006){ref-type="fig"} and [7](#pone-0106418-g007){ref-type="fig"}). IRF7 is the master regulator of type I IFN-dependent immune responses [@pone.0106418-Honda1] and plays an important role in HIV-1 pathogenesis [@pone.0106418-Sirois1]. IRF7 promotes autocrine and paracrine activation of STAT1 and plays a critical role in virus-mediated induction of IFN-α [@pone.0106418-Marie1]. It is known that type I IFNs activate the Janus kinases (JAKs) and the STAT transcription factors, which ultimately leads to the expression of target genes [@pone.0106418-Shuai1], [@pone.0106418-Takeda2]. The *STAT1* gene encodes a 91-kDa protein which is activated by both type I and type II IFNs [@pone.0106418-Pilz1]. This important transcription factor is phosphorylated by the JAKs in response to proinflammatory and regulatory factors [@pone.0106418-Darnell1]. It has been shown that the STAT1 pathway plays an important role in the pathogenesis of HIV-1 infection [@pone.0106418-Bovolenta1], [@pone.0106418-Chaudhuri1]; indeed, activation of the STAT1 pathway by HIV-1 Vpr is demonstrated in this study. We further showed that in the presence of Vpr protein the level of STAT1 phosphorylation at tyrosine 701 is much higher than the control recombinant adenovirus ([Figure 7](#pone-0106418-g007){ref-type="fig"}). The exact mechanism through which Vpr leads to the phosphorylation of STAT1 at tyrosine 701 is not known and requires further study.

HIV-1 Vpr protein caused the up-regulation of various ISGs, such as ISG15 and ISG20 ([Figures 6](#pone-0106418-g006){ref-type="fig"} and [7](#pone-0106418-g007){ref-type="fig"}), which can inhibit virus replication through different mechanisms [@pone.0106418-Schoggins1], [@pone.0106418-Sadler1]. Previously, it has been shown that HIV-1 Vpr protein activates NF-κB [@pone.0106418-Ayyavoo2], which might explain the up-regulation of various ISGs in our study. The ISGs act through a variety of mechanisms to render cells resistant to viral infection [@pone.0106418-Schoggins1]. It has been shown that ISG15 is induced in HIV-1-infected MDMs [@pone.0106418-Schoggins1], where it restricts and impedes HIV-1 replication by causing ISGylation of viral Gag protein and certain cellular factors [@pone.0106418-Pincetic1]. Similarly, ISG20 has been shown to exhibit antiviral activity against HIV-1 [@pone.0106418-Espert1]. Induction and activation of ISGs such as ISG15, ISG20, the IFITs, and viperin are thought to be the reason MDMs are relatively resistant to cell death and can act as long-term carriers of HIV-1 [@pone.0106418-Nasr1]. The observation that these genes were up-regulated in Ad-Vpr-infected MDMs in our study suggests that in HIV-1-infected macrophages, Vpr is responsible for the induction of these ISGs; thus due to these ISGs, macrophages are relatively resistant to Vpr-induced cell death.

TRAIL protein is produced after HIV-1 infection in monocytes due to the IFNα/β-mediated activation of the STAT1 signaling cascade [@pone.0106418-Herbeuval1], and has been shown to cause apoptosis in several cell lines during HIV-1 infection. Although an initial increase in TRAIL protein was shown to kill HIV-1-infected macrophages [@pone.0106418-Lum1], the exact role of TRAIL-mediated apoptosis in the elimination of HIV-1-infected cells is not known. Here, we have shown that HIV-1 Vpr protein caused elevated levels of TRAIL protein in macrophages ([Figures 6](#pone-0106418-g006){ref-type="fig"} and [7](#pone-0106418-g007){ref-type="fig"}), which would presumably help to eliminate HIV-1-infected cells through TRAIL-mediated cell death [@pone.0106418-Huang1], [@pone.0106418-Lum1]--[@pone.0106418-Laforge1].

Our findings further demonstrated that HV-1 Vpr differentially regulated the expression levels of chemotactic cytokines such as *CXCL1, CXCL5, CXCL7, CXCL9, CXCL10*, and *CXCL11* ([Table 1](#pone-0106418-t001){ref-type="table"}). A previous report has shown that *CXCL10* and *CXCL11* are up-regulated in HIV-1-infected macrophages and play a key role in the recruitment and spread of HIV-1 to susceptible CD4^+^ T-cells [@pone.0106418-Foley1]. Surprisingly, our microarray data also showed that *CXCL10* and *CXCL11* were up-regulated in MDMs, by 23-fold and 7-fold, respectively ([Table 1](#pone-0106418-t001){ref-type="table"}). Whether HIV-1 Vpr has a role in HIV-1 dissemination and the mechanism through which Vpr leads to the differential regulation of these chemokines in MDMs is not known. However, the recruitment of susceptible T-cells by HIV-1-infected human macrophages and the role of CXCL10 and CXCL11 will be intriguing to investigate in future studies.

HIV-1 Vpr is essential for efficient infection of non-dividing cells such as macrophages. It has been shown that HIV-1 Vpr is expressed within infected cells and is packaged into HIV-1 virions. Although, the virion-associated Vpr is able to cause cell cycle arrest of CD4^+^ T cells in vivo [@pone.0106418-Poon1], the induction of ISGs by this biologically active form of Vpr is not known. However, our recent studies have confirmed that the induction of ISGs in HIV-1~AD8~/Vpr^+^ infected MDMs (Unpublished results) is similar to ISGs induced by Vpr in Ad-Vpr infected MDMs. Our data indicating that Vpr leads to the induction of ISGs and activation of innate immune responses is contrary to some of the previously published reports which showed that Vpr helps HIV-1 to escape the innate immune responses by either counteracting the UNG2, a host cellular intrinsic factor which inhibits HIV-1 replication [@pone.0106418-Fenard1]--[@pone.0106418-Nekorchuk1] or by manipulating the cellular SLX4 complex which is a negative regulator of Type 1 IFN production [@pone.0106418-Laguette1]. Therefore, the complex role played by Vpr in escaping HIV-1 virions from innate immune responses or by activating innate immunity through inducing ISGs in HIV-1 infected macrophages must be investigated in future studies.

Our data confirmed that HIV-1 Vpr leads to the induction of ISGs in MDMs. However, our findings showed some donor-specific differences in the expression profiles of these ISGs, which might be due to differences in overall susceptibility and the host response to the HIV-1 Vpr infection. These differences and the number of donors used in the study should not be considered a limiting factor because the expression profiles of the selected genes in all donors were independently confirmed by qRT-PCR with reproducible and consistent readouts each time ([Figure 6](#pone-0106418-g006){ref-type="fig"}). Furthermore, we cannot rule out the possibility that some of these ISGs are regulated by direct or indirect interactions of Vpr with cellular proteins related to the innate immune response, including cellular transcription factors such as NF-κB, AP-1, and Sp-1 [@pone.0106418-Herbein1], [@pone.0106418-Ayyavoo2].

In conclusion, our studies have identified IRF7, STAT1, ISG15, ISG20, and TRAIL as key up-regulated molecules in MDMs harboring HIV-1 Vpr. Based on previous published reports and our present data; we suggest a potential role for these genes in host defense against HIV-1 replication and infection. Future studies to elucidate the mechanisms through which Vpr up-regulates these molecules as well as their roles in HIV-1 pathogenesis will certainly improve our understanding of the replication and pathogenesis of the HIV-1.

Materials and Methods {#s4}
=====================

Cell culture and preparation of human MDMs {#s4a}
------------------------------------------

Human cervical HeLa cells and human embryonic kidney HEK-293 cells were maintained in Dulbecco\'s modified Eagle\'s medium (DMEM; Life Technologies) supplemented with 10% heat-inactivated fetal bovine serum (FBS; Sigma) and 100 units/mL penicillin/streptomycin (Sigma). Plasmid transfection was performed using Lipofectamine 2000 (Life Technologies).

Human PBMCs were obtained using a standard Ficoll-Paque (Pharmacia) gradient from heparinized blood from healthy individuals. CD14^+^ cells were isolated by positive selection with anti-human CD14^+^ magnetic beads (MACS system; Miltenyi Biotec). Purity was greater than 95% (data not shown). Primary MDMs were generated by culturing CD14^+^ cells in RPMI 1640 medium (Sigma) supplemented with 10% FBS (Cell Culture Bioscience), 5% human AB serum(Sigma), antibiotics, and GlutaMax (Gibco), and containing recombinant human macrophage colony-stimulating factor (M-CSF; PeproTech). After 7 days, cellular differentiation status was confirmed by detection of MDM surface such as CD14 and CD68 (data not shown). All participants provided written informed consent. Ethics approval for this study was granted by the RIKEN Ethics Committees \[Certificate No. Wako 21--2 (3)\].

Antibodies {#s4b}
----------

STAT1 (\#9172), phospho-STAT1 (Tyr701; \#9171), and IRF-7 (\#4920) rabbit polyclonal antibodies were from Cell Signaling Technology. The ISG15 mouse monoclonal antibody (MAb) (\#AIS0701) was from ATGen. The TRAIL rabbit polyclonal antibody (\#54008) was from ANASPEC. The ISG20 rabbit polyclonal antibody (\#ARP40392-T100) was from Aviva System Biology. The HIV-1 Vpr mouse MAb \#3 was produced by immunization of synthetic peptides N\'-CQAPEDQGPQREPYN-C\' corresponding to amino acids 3--16 of Vpr. The APOBEC3A goat polyclonal antibody (\#NB100-93428) was from Novus Biologicals. ZsGreen1 rabbit polyclonal antibody (\#632474) was from Clontech Laboratories. Fluorescein isothiocyanate (FITC)-conjugated MAbs directed against the human surface markers CD14 and CD68 were from Miltenyi Biotec and used at the supplier\'s recommended concentrations. The β-actin (\#1978) MAb and *horseradish peroxidase* (HRP)-labeled donkey anti-goat or goat anti-mouse secondary antibodies were from Sigma.

Generation of recombinant adenoviruses {#s4c}
--------------------------------------

Adenoviruses were constructed using the Adeno-X™ expression system (Clontech Laboratories). Briefly, wild-type (wt) Vpr from HIV-1~NL43~ [@pone.0106418-Adachi1] (GenBank accession no. M 19921) was PCR-amplified with the FLAG tag incorporated using the primers GAAGCTAGCGACTACAAGGATGACGATGACAAAATGGAACAAGCCCCAGAAGA (forward) and GCTCTAGACTAGGATCTACTGGCTCCAT (reverse), and cloned into the pShuttle2 vector at the *Nhe*I and *Xba*I restriction sites. Similarly, the ZsGreen1 gene was PCR-amplified with the FLAG tag incorporated using the primers TAATCTAGAGACTACAAGGATGACGATGACAAAGCCCCTCTCCCTCCCCCCCCCCTAA (forward) and TAGCGGCCGCTCAGGGCAAGGCGGAGCCGGAG (reverse) using the pRetroX-IRES2-ZsGreen1 plasmid (Clontech Laboratories) as a template, and then cloned into the pShuttle vector just downstream of Vpr at the *XbaI* and *Not*I restriction sites. The integrity of the generated recombinant plasmids was confirmed by DNA sequencing. Then the entire cassette (flanked by unique I-*Ceu*I and PI-*Sce*I restriction sites) was excised and ligated into Adeno-X viral DNA using the Adeno-X expression system 1, according to the manufacturer\' s instructions (Clontech Laboratories).

Adeno-X viral DNA containing the FLAG-Vpr or ZsGreen1 was linearized with *Pac*I and transfected into HEK293 cells with Lipofectamine 2000 (Life Technologies). The recombinant adenoviruses were purified using the Adeno-X maxi purification kit (Clontech Laboratories) and titrated using the Adeno-X rapid titer kit (Clontech Laboratories), following the recommendations of the manufacturer. The virus stocks were stored at −80°C for future use.

RNA extraction {#s4d}
--------------

MDMs were transduced with Ad-Vpr or Ad-Zs at a MOI of 100. The cells were harvested for RNA extraction at 48 h post-transduction. MDMs were washed three times with ice-cold PBS, and total RNA was extracted using the RNeasy mini kit with DNase digestion, according to the manufacturer\'s instructions (QIAGEN). RNA was quantified using a NanoDrop spectrophotometer (Thermo Fisher) and stored at −80°C. For microarray analysis, the quality of the RNA was determined using the Agilent Bioanalyzer (Agilent Technologies).

Microarray and data analysis {#s4e}
----------------------------

RNA samples were analyzed by microarray using the GeneChip Human Genome U133 2.0 plus array (Affymetrix). Microarray hybridization and fluorescence detection were performed as described in the Affymetrix GeneChip Expression Analysis Technical Manual. The. cel data files generated by the Affymetrix microarray hybridization platform were analyzed using GeneSpring GX ver. 12.0 software (Agilent Technologies). Probe-level analysis was performed using the RMA algorithm. Microarray data have been deposited in NCBI\'s Gene Expression Omnibus and assigned the GEO Series accession number GSE56591. Fold changes in gene expression, hierarchical clustering, and gene ontology annotations were determined.

Real-time qRT-PCR analysis of differentially expressed genes {#s4f}
------------------------------------------------------------

Total RNA was prepared using the RNeasy mini kit as described above. RT-PCR was performed using specific primers and One-Step SYBR Green PCR mix (Takara), according to the manufacturer\'s manual. qRT-PCR was performed using a Prism 7500 sequence detection system (Applied Biosystems). Samples were run in triplicate and all data were normalized to *GAPDH* mRNA expression as an internal control.

Western blotting {#s4g}
----------------

Mock or virus-infected MDMs were washed with PBS and then lysed with CelLytic™ MT Cell Lysis reagent (Sigma) which was supplemented with a protease inhibitor cocktail (Roche Diagnostics) according to the manufacturer\'s instructions. Protein concentrations were determined with a BCA protein assay kit (Pierce) using bovine serum albumin as a standard. Proteins were separated by sodium dodecyl sulfate-10% polyacrylamide gel electrophoresis (SDS-PAGE) and transferred to polyvinyl difluoride (PVDF; Millipore Corp.) membranes. The PVDF membranes were probed with the primary antibodies mentioned above followed by an anti-mouse HRP or anti-goat HRP or anti-rabbit HRP secondary antibody (Sigma), and signals were detected by enhanced chemiluminescence (GE Healthcare).

Analysis of the cell cycle {#s4h}
--------------------------

HeLa cells were infected with an adenoviral vector expressing Vpr or expressing only ZsGreen1, as a control. At 48 h post-infection, the cells were harvested and fixed with 1% formaldehyde followed by 70% ethanol. Fixed cells were incubated in PBS containing RNase A (50 *µ*g/ml) at 37°C for 20 min and then stained with PI (40 *µ*g/ml). For each sample, at least 7,000 cells were analyzed using a FACS Calibur instrument (Becton-Dickinson) with CELL Quest software (Becton-Dickinson). Ratios of the numbers of cells in the G1 and G2/M phases (G2+M: G1 ratios) were calculated using ModFit LT Software (Verity Software House).
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